| MDL | MFCD22124519 |
|---|---|
| Molecular Weight | 479.51 |
| Molecular Formula | C23H21N5O5S |
| SMILES | COC1=C(OC(C(NS(C2=NC=C(C=C2)C)(=O)=O)=NC(C3=CC=NC=C3)=N4)=C4OC)C=CC=C1 |
Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist. IC50 value: Target: ETA receptor
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00120328 | Speedel Pharma Ltd. |
Diabetic Nephropathy
|
July 2005 | Phase 3 |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 6.67 mg/mL ( 13.91 mM ; Need ultrasonic)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0855 mL | 10.4273 mL | 20.8546 mL |
| 5 mM | 0.4171 mL | 2.0855 mL | 4.1709 mL |
| 10 mM | 0.2085 mL | 1.0427 mL | 2.0855 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 0.67 mg/mL (1.40 mM); Clear solution